Travel vaccines, also called travel immunizations, are shots travelers can get before visiting certain areas of the world that help protect them from serious illnesses. Vaccinations work by exposing the body to germs or parts of germs of the disease it will protect against. Travel vaccines are safe, effective ways to help protect travelers from bringing home more than they bargained for. These vaccines are recommended to provide protection against diseases endemic to the country of origin or of destination. They are intended to protect travelers and to prevent disease spread within and between countries. Some countries require proof of vaccination for travelers wishing to enter or exit the country.
GlaxoSmithKline plc. And Sanofi – Notable Market Players in Travel Vaccines Market
Leading companies operating in the market have undertaken various organic growth strategies in the travel vaccines market. The travel vaccines market is majorly comminated by GlaxoSmithKline plc; Merck & Co., Inc; Sanofi; Novartis AG; Pfizer Inc; Dynavax Technologies; Emergent BioSolutions Inc; Abbott; BHARAT BIOTECH, and Valneva SE amongst others. The companies have been implementing various strategies that have helped their growth and, in turn, brought about several breakthroughs and transitions in the industry. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the market players have also deployed several utilized inorganic strategies, including mergers & acquisitions, partnerships, and collaborations.
Below are the major growth strategies undertaken by the players operating in the global travel vaccines market:
| Year | News |
| Dec-2021 | Emergent BioSolutions Inc. announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate. The current version of the influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses. |
| Dec-2021 | GlaxoSmithKline (GSK) plc welcomed the decision of the Gavi Board to provide funding for the procurement and introduction of malaria vaccines into routine child immunisation programmes in Gavi eligible countries. The announcement followed shortly after WHO recommendation for the broader use of GSK’s RTS,S/AS01e to reduce childhood illness and deaths from malaria in children living in sub-Saharan Africa and other regions. |
| Oct-2020 | Merck new clinical and epidemiological data from its broad infectious diseases and vaccines program was presented at IDWeek 2020. Clinical data include new subgroup analyses from the Phase 3 RESTORE-IMI 2 trial evaluating the safety and efficacy of RECARBRIO, and a new pooled analysis of the safety and efficacy of PIFELTRO (doravirine) or DELSTRIGO in adults 50 years of age and older living with HIV-1 who are treatment-naïve. |
| Dec-2019 | GlaxoSmithKline plc completed the divestment of travel vaccines Rabipur for the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic. GSK received an upfront payment of USD 348 million. |
